Inicio/Acciones/KYMR

KYMR

USD

Kymera Therapeutics Inc. Common Stock

$60.670+4.870 (8.728%)

Precio en Tiempo Real

Healthcare

Biotecnología

Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$55.800

Máximo

$61.580

Mínimo

$55.660

Volumen

0.77M

Fundamentos de la Empresa

Capitalización de Mercado

4.3B

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.75M

Bolsa

NGM

Moneda

USD

Rango de 52 Semanas

Mínimo $19.445Actual $60.670Máximo $63.96

Noticias Relacionadas

3 nov 2025 · 13:14

Analyst Upgrades

Guggenheim Assumes Kymera Therapeutics at Buy, Announces Price Target of $90

Guggenheim analyst Brad Canino assumes Kymera Therapeutics with a Buy rating and announces Price Target of $90.

Guggenheim Assumes Kymera Therapeutics at Buy, Announces Price Target of $90

3 nov 2025 · 12:00

GlobeNewswire

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

27 oct 2025 · 11:00

GlobeNewswire

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically